UK Biotech Data Shows Positive Start to 2020
Prior to the global market downturn, data from the United Kingdom BioIndustry Association (BIA) and Informa Pharma Intelligence have revealed that biotech companies in the UK had raised £309 million (US$379 million).
Prior to the global market downturn, data from the United Kingdom BioIndustry Association (BIA) and Informa Pharma Intelligence have revealed that biotech companies in the UK had raised £309 million (US$379 million).
It was revealed in a March 27, 2020 press release that the total funds raised had been boosted by strong secondary financings on public markets in both the UK and the United States. Data was taken between December 2019 and the end of February 2020.
“This was a positive start to the year but it is clear there are challenging times ahead for all sectors as governments and global markets respond to the coronavirus crisis,” said Steve Bates, CEO of BIA, in the press release. “It’s great to see some strong fundraises by UK companies, like Adaptimmune, Freeline, and Oxford Nanopore, which will put them and their research programs in a good position for the year ahead. For others, as funds look likely to be harder to come by in the short-to-medium term, the value of R&D tax credits and innovation grants from the government become even more crucial to maintain the pipeline of research and innovation that ultimately leads to new medicines, vaccines, and diagnostics for patients.”
Source: BIA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
